Objective: To analyze the risk factors for bloodstream infection after immunosuppressive therapy in patients with aplastic anemia using logistic regression.
Methods: A retrospective analysis was conducted on the clinical data from 70 patients with aplastic anemia admitted to the People's Hospital of Zitong County and the Infectious Disease Hospital in Jiangyou City from March 2011 to March 2023. Patients were divided into two groups based on whether they developed an infection after treatment: the infection group (n = 18) and the non-infection group (n = 52). Risk factors for bloodstream infection following immunosuppressive therapy were analyzed, and the predictive value of independent risk factors was assessed.
Results: Univariate analysis identified age, diabetes, disease severity, albumin levels, neutrophil count, and concurrent infections before treatment as significant risk factors for bloodstream infection following immunosuppressive therapy (all P<0.05). Multivariate analysis further confirmed that age, diabetes, disease severity, albumin levels, and neutrophil count were independent risk factors for bloodstream infection (all P<0.05). ROC curve analysis revealed that age, diabetes, disease severity, albumin levels, and neutrophil count had area under the curve (AUC) values of 0.678, 0.728, 0.698, 0.740, and 0.739, respectively, in predicting bloodstream infection after immunosuppressive therapy. The sensitivity values were 65.39%, 78.85%, 67.31%, 67.31%, and 76.92%, respectively, while the specificity values were 72.22%, 66.67%, 72.22%, 77.78%, and 61.11%, respectively.
Conclusion: Age, diabetes, disease severity, albumin levels, and neutrophil count are key factors influencing bloodstream infection after immunosuppressive therapy in patients with aplastic anemia. These findings highlight the need for careful monitoring of these factors during immunosuppressive therapy to reduce the risk of bloodstream infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558360 | PMC |
| http://dx.doi.org/10.62347/URKZ2878 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epstein-Barr Virus-Induced Hemophagocytic Lymphohistiocytosis: A Case Report of a Rare and Life-Threatening Syndrome.
Cureus
December 2024
Internal Medicine Department, Hamad Medical Corporation, Doha, QAT.
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening syndrome of excessive immune activation, leading to severe inflammation and organ damage. While more common in infants, HLH can occur at any age and is often triggered by infections such as Epstein-Barr virus (EBV). In this case, a 38-year-old man presented with a three-week history of fevers, night sweats, poor appetite, and severe anemia.
View Article and Find Full Text PDF. Extract Attenuates Inflammation and Oxidative Damage in Cisplatin-Induced Cardiotoxicity in Rats by Promoting M2 Macrophage Polarization.
Mediators Inflamm
January 2025
Faculty of Medical Sciences, Department of Genetics, University of Kragujevac, Kragujevac, Serbia.
L. fruits and leaf extracts have a broad range of immunomodulatory, anti-inflammatory, and antioxidant effects; however, their effects on cardiac protection have not been investigated. The study aims to test the biological activity of L.
View Article and Find Full Text PDFUse of immunosuppression and subsequent cancer incidence: cohort study.
BMJ Oncol
August 2023
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Objective: Evaluate the association between cancer incidence and immunosuppressive treatment in patients with ocular inflammatory disease (OID).
Methods And Analysis: We performed a retrospective cohort study of patients from 10 US OID subspecialty practices. Patients with non-infectious OID were included; HIV-infected patients were excluded.
Clinical Characteristics and Outcomes of Patients with Anti-MDA5 Antibody Associated Rapidly Progressive Interstitial Lung Disease (RP-ILD): A Case Series.
Mediterr J Rheumatol
December 2024
Department of Internal Medicine, Government Medical College Kottayam, Kerala, India.
Objective: To describe the clinical profile and treatment outcomes of a longitudinal series of patients with rapidly progressive interstitial lung disease (RP-ILD) associated with anti MDA 5 antibody.
Methods: RP-ILD patients were identified from a prospective cohort of adult patients with idiopathic inflammatory myopathy (IIM). Clinical, demographic, and serological parameters of all patients were recorded using a structured proforma.
Improved Clinical Outcomes with Appropriate Meropenem De-escalation in Patients with Febrile Neutropenia.
J Glob Infect Dis
December 2024
Department of Internal Medicine, Division of Infectious Diseases, Loyola University Medical Center, Maywood, IL, USA.
Introduction: Antibiotic stewardship is a critical aspect of managing cancer patients with febrile neutropenia (FN) to limit the development of drug-resistant organisms and minimize adverse drug effects. Thus, it has been recommended that patients with FN receiving empiric antibiotics should be re-evaluated for safe antibiotic de-escalation.
Methods: Subjects treated with meropenem for febrile neutropenia who met Loyola University Medical Center's (LUMC) criteria for de-escalation were stratified based on whether meropenem was de-escalated, and 30-day all-cause mortality for both groups was assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!